BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 221 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.69 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $36,344,522 | -4.4% | 5,133,407 | -5.0% | 0.02% | +5.6% |
| Q2 2023 | $38,036,557 | +96251.2% | 5,402,920 | +14.1% | 0.02% | -18.2% |
| Q1 2023 | $39,477 | +2852.7% | 4,733,429 | +3963.3% | 0.02% | +2100.0% |
| Q4 2022 | $1,337 | -100.0% | 116,491 | -91.2% | 0.00% | -90.0% |
| Q3 2022 | $16,713,000 | -18.9% | 1,326,442 | -31.9% | 0.01% | -23.1% |
| Q2 2022 | $20,616,000 | +2206.0% | 1,948,595 | +3445.8% | 0.01% | – |
| Q1 2022 | $894,000 | -44.3% | 54,955 | -52.6% | 0.00% | -100.0% |
| Q4 2021 | $1,604,000 | -73.5% | 115,834 | -72.5% | 0.00% | -75.0% |
| Q3 2021 | $6,062,000 | -46.4% | 421,853 | -41.0% | 0.00% | -42.9% |
| Q2 2021 | $11,306,000 | +2677.9% | 715,140 | +1687.8% | 0.01% | – |
| Q1 2021 | $407,000 | -80.9% | 40,000 | -86.0% | 0.00% | -100.0% |
| Q4 2020 | $2,135,000 | -81.7% | 286,632 | -91.6% | 0.00% | -85.7% |
| Q3 2020 | $11,658,000 | -66.1% | 3,393,912 | -53.0% | 0.01% | -70.2% |
| Q2 2020 | $34,382,000 | +161.8% | 7,215,541 | +9.9% | 0.05% | +56.7% |
| Q1 2020 | $13,133,000 | -61.8% | 6,566,441 | -34.2% | 0.03% | -30.2% |
| Q4 2019 | $34,415,000 | +50.6% | 9,975,477 | +25.1% | 0.04% | +19.4% |
| Q3 2019 | $22,845,000 | -23.7% | 7,974,335 | +1.0% | 0.04% | -20.0% |
| Q2 2019 | $29,927,000 | +87.9% | 7,896,297 | +303.5% | 0.04% | +87.5% |
| Q1 2019 | $15,928,000 | +144.3% | 1,956,785 | +142.2% | 0.02% | +140.0% |
| Q4 2018 | $6,521,000 | -27.6% | 808,027 | -31.5% | 0.01% | -9.1% |
| Q3 2018 | $9,002,000 | -7.3% | 1,179,807 | -30.4% | 0.01% | -15.4% |
| Q2 2018 | $9,714,000 | -24.3% | 1,695,333 | -37.0% | 0.01% | -23.5% |
| Q1 2018 | $12,833,000 | -29.5% | 2,690,255 | -27.5% | 0.02% | -32.0% |
| Q4 2017 | $18,214,000 | -7.5% | 3,709,542 | -1.2% | 0.02% | -16.7% |
| Q3 2017 | $19,682,000 | +3.9% | 3,756,165 | +10.3% | 0.03% | -11.8% |
| Q2 2017 | $18,937,000 | -25.8% | 3,405,864 | +12.1% | 0.03% | -27.7% |
| Q1 2017 | $25,525,000 | +2055.8% | 3,038,649 | +1525.0% | 0.05% | +2250.0% |
| Q4 2016 | $1,184,000 | -25.7% | 186,994 | -48.2% | 0.00% | 0.0% |
| Q3 2016 | $1,593,000 | +1774.1% | 361,156 | +1101.1% | 0.00% | – |
| Q2 2016 | $85,000 | -91.7% | 30,068 | -91.7% | 0.00% | -100.0% |
| Q1 2016 | $1,025,000 | -42.7% | 362,289 | +109.1% | 0.00% | -25.0% |
| Q4 2015 | $1,788,000 | -83.6% | 173,252 | -81.9% | 0.00% | -81.0% |
| Q3 2015 | $10,886,000 | -62.0% | 954,888 | -50.2% | 0.02% | -61.1% |
| Q2 2015 | $28,621,000 | +30.4% | 1,917,021 | -21.1% | 0.05% | +31.7% |
| Q1 2015 | $21,953,000 | +1899.4% | 2,431,123 | +2593.2% | 0.04% | +1950.0% |
| Q4 2014 | $1,098,000 | -61.3% | 90,268 | -68.9% | 0.00% | -71.4% |
| Q3 2014 | $2,837,000 | +50.0% | 290,114 | +95.6% | 0.01% | +40.0% |
| Q2 2014 | $1,891,000 | -69.7% | 148,298 | -74.9% | 0.01% | -72.2% |
| Q1 2014 | $6,240,000 | +27.5% | 589,752 | -8.4% | 0.02% | +20.0% |
| Q4 2013 | $4,893,000 | +173.7% | 643,755 | +162.1% | 0.02% | +150.0% |
| Q3 2013 | $1,788,000 | – | 245,592 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 1,105,673 | $8,237,000 | 6.28% |
| Sarissa Capital Management LP | 8,175,000 | $60,903,000 | 6.22% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,980,870 | $22,207,000 | 2.78% |
| DG Capital Management, LLC | 1,075,732 | $8,014,000 | 1.70% |
| Ghost Tree Capital, LLC | 900,000 | $6,705,000 | 1.49% |
| Parkman Healthcare Partners LLC | 538,370 | $4,011,000 | 1.03% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 5,835,810 | $43,477,000 | 0.86% |
| Formidable Asset Management, LLC | 470,419 | $3,470,000 | 0.80% |
| KNOTT DAVID M | 219,461 | $1,635,000 | 0.74% |
| Altium Capital Management LP | 250,000 | $1,863,000 | 0.70% |